Copyright
©2014 Baishideng Publishing Group Co., Limited. All rights reserved.
World J Gastroenterol. May 7, 2014; 20(17): 4980-4986
Published online May 7, 2014. doi: 10.3748/wjg.v20.i17.4980
Published online May 7, 2014. doi: 10.3748/wjg.v20.i17.4980
Histological healing favors lower risk of colon carcinoma in extensive ulcerative colitis
Burton I Korelitz, Megha Kothari, Judy Schneider, Department of Gastroenterology, Lenox Hill Hospital, New York, NY 10075, United States
Keith Sultan, Department of Gastroenterology and Hepatology and Nutrition, North Shore Hospital, Manhasset, NY 11030, United States
Leo Arapos, North Oaks Medical Center, Hammond, LA 70403, United States
Georgia Panagopoulos, Department of Research, Lenox Hill Hospital, New York, NY 10075, United States
Author contributions: Korelitz BI developed the study, provided the data and created and edited the manuscript; Sultan K co-edited the manuscript; Kothari M entered the data for the study; Arapos L entered the data for the study; Schneider J assembled the data for the manuscript; Panagopoulos G provided the statistical evaluation of the data.
Supported by New York Crohn’s Foundation
Correspondence to: Burton I Korelitz, MD, Chief Emeritus, Director of Research in IBD, Department of Gastroenterology, Lenox Hill Hospital, 100 East 77th Street, 6 Black Hall, New York, NY 10075, United States. bkorelitz@nshs.edu
Telephone: +1-212-4342063 Fax: +1-212-4342446
Received: September 25, 2013
Revised: October 24, 2013
Accepted: November 12, 2013
Published online: May 7, 2014
Revised: October 24, 2013
Accepted: November 12, 2013
Published online: May 7, 2014
Core Tip
Core tip: Patients with long standing and extensive ulcerative colitis who develop colon cancer rarely have histological healing despite gross endoscopic healing. The persistence of histological inflammation is common in those who develop colon cancer (CC) or high grade dysplasia (HGD). When surveillance colonoscopies in ulcerative colitis of 20 years duration reveal persistent histological inflammation, patients are at high risk for the development of CC/HGD. Consideration of increasing drug therapy should arise, and the patient is entitled to share in this knowledge and contribute to the decision.